ENTITY

Newron Pharmaceuticals (NWRN SW)

32
Analysis
Health CareItaly
Newron Pharmaceuticals SpA is a research and development biopharmaceutical company. The Company focuses on and develops therapies for the Central Nervous System (CNS) in cases such as Parkinson's disease, neuropathic low back pain and other cognitive disorders.
more
23 Sep 2024 19:10Issuer-paid

Newron Pharmaceuticals - Moving full steam towards pivotal studies

Newron Pharmaceuticals’ H124 results reflect a period of positive traction for lead clinical asset evenamide, with stellar clinical data as an...

Share
27 Jun 2024 01:10Issuer-paid

Newron Pharmaceuticals - Evenamide road to registration and beyond

Newron hosted an investor day (25 June) featuring three key opinion leaders (KOLs) who highlighted evenamide’s unique mechanism at the site of...

Share
14 May 2024 19:10Issuer-paid

Newron Pharmaceuticals - Evenamide potential for treatment of schizophrenia

Newron Pharmaceuticals has released additional data from its Phase II/III trial (study 008A), providing further evidence to support evenamide’s...

Share
02 May 2024 01:10Issuer-paid

Newron Pharmaceuticals - Evenamide notches up another win (study 008A)

Newron Pharmaceuticals has shared positive top-line data for its evenamide programme from its potentially pivotal Phase II/III trial (study 008A)...

Share
21 Mar 2024 01:10Issuer-paid

Newron Pharmaceuticals - Evenamide set for a pivotal year

Newron Pharmaceuticals has reported results for FY23, an active period for its lead asset, evenamide, being developed for treatment-resistant...

Share
x